TriSalus Life Sciences Reports Strong Q4 Revenue Beat, Narrows Losses
TriSalus Life Sciences Inc (NASDAQ:TLSI) announced its fourth quarter and full-year 2025 financial results after the market close on March 5, 2026, delivering a top-line revenue figure that modestly exceeded analyst expectations while showing significant year-over-year growth. The oncology-focused medical technology company also provided a reaffirmed revenue outlook for the coming year.
Earnings and Revenue Versus Estimates
The company's performance for the final quarter of 2025 presented a mixed but generally positive picture against Wall Street forecasts. TriSalus reported net sales of $13.2 million, marking a substantial 60% increase compared to the fourth quarter of 2024. This result slightly surpassed the analyst consensus estimate of approximately $13.17 million.
On the profitability front, the company reported a net loss attributable to common stockholders of $9.8 million, or a loss of $0.21 per basic and diluted share. This compares to a net loss of $10.9 million, or $0.40 per share, in the prior year period. The press release also highlighted an improved Adjusted EBITDA loss of $0.9 million for the quarter, a significant improvement from a loss of $5.7 million in Q4 2024. While the GAAP earnings per share (EPS) figure is not directly comparable to the provided non-GAAP EPS estimate, the company's progress on narrowing its operating and adjusted losses was a key theme.
Market Reaction and Price Action
Following the earnings release, the market's immediate reaction in after-hours trading appeared neutral, with no significant price movement indicated. This muted response suggests investors may have anticipated the solid results or are focusing on the company's longer-term execution and path to profitability. Over recent weeks, the stock has shown modest volatility, with a slight decline over the past week but a small gain over the past two weeks.
Full-Year 2025 Performance and 2026 Outlook
For the full year 2025, TriSalus reported total revenue of $45.2 million, a 53% increase over 2024 and exceeding the company's own growth guidance of 50%. The company's strategic focus on its TriNav® product suite and proprietary Pressure-Enabled Drug Delivery (PEDD®) platform drove this growth, primarily within liver-directed cancer therapies.
Looking ahead, management reaffirmed its 2026 revenue guidance in the range of $60 million to $62 million. This outlook implies a growth rate of approximately 33% at the midpoint. It is important to note that the company's provided guidance is a revenue figure, while the analyst estimate provided in the context is an EPS estimate for 2026. The company's guidance aligns with the broader analyst expectation for continued strong sales growth in the coming year.
Key Highlights from the Press Release
Beyond the financial figures, the earnings release underscored several operational milestones and strategic initiatives:
- Strong Commercial Momentum: Continued expansion in the use of the TriNav system for liver embolization and development of new applications in interventional radiology.
- Strengthened Balance Sheet: Subsequent to the quarter end, the company raised $46 million in gross proceeds through a public offering, bolstering its cash position to fund growth initiatives.
- Product Innovation: Launched the TriNav XP Infusion System, designed for compatibility with larger embolic particles.
- Improved Financial Metrics: Gross margin remained robust at 86.7% for Q4, and operating losses decreased significantly year-over-year, demonstrating operating leverage as revenue scales.
Conclusion
TriSalus Life Sciences' fourth-quarter results reflect a company in a strong growth phase, successfully commercializing its proprietary drug delivery technology in the oncology space. The revenue beat and significantly improved adjusted EBITDA highlight effective execution. The reaffirmed 2026 sales guidance provides visibility into continued expansion, though investor attention will likely remain on the company's ability to further narrow losses and achieve profitability on its stated timeline. The recent capital infusion provides additional runway to accelerate strategic plans.
For a detailed look at historical earnings, future estimates, and additional financial metrics, you can review the TriSalus Life Sciences earnings page here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
